Biochemical Basis for the Antagonism between Aminoglutethimide and Danazol in the Endocrine Treatment of Breast Cancer

In: Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · 1986 · vol. 23(3) , pp. 277–284 · doi:10.1177/000456328602300306 · PMID:3789634 · W2320751946
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-13

The combination of aminoglutethimide and danazol showed reduced breast cancer patient response compared to aminoglutethimide alone due to danazol's suppression of sex hormone binding-globulin leading to increased free estradiol.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Only 13% of postmenopausal advanced breast cancer patients responded to endocrine treatment with aminoglutethimide plus danazol whilst 33% responded to aminoglutethimide alone, despite a similar suppression of serum oestradiol levels in the two groups. The patients on aminoglutethimide and danazol showed a marked suppression of sex hormone binding-globulin binding capacity and a consequent rise in percent-free oestradiol. This led to the concentration of free oestradiol being less well suppressed than that of total oestradiol and in some patients free oestradiol concentrations were higher on treatment than before. Patients on aminoglutethimide alone showed no change in the binding of oestradiol and the percentage suppression of the free oestradiol concentration was similar to that of total oestradiol. The opposing effects of danazol and aminoglutethimide on the concentration of the free, biologically active fraction of oestradiol in the circulation may explain the poor therapeutic efficacy of this combination in breast cancer patients.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (20)

Source provenance

openalex
last seen: 2026-05-10T12:02:58.567994+00:00
License: CC0 · commercial use OK